Merck & Company, Inc. (MRK) Holdings Boosted by Catawba Capital Management VA

Catawba Capital Management VA raised its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 5.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,138 shares of the company’s stock after acquiring an additional 3,312 shares during the period. Catawba Capital Management VA’s holdings in Merck & were worth $3,790,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. HM Capital Management LLC increased its position in shares of Merck & by 0.4% during the 1st quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock valued at $236,000 after purchasing an additional 15 shares during the last quarter. Bath Savings Trust Co increased its position in shares of Merck & by 0.5% during the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after purchasing an additional 28 shares during the last quarter. City Holding Co. increased its position in shares of Merck & by 0.4% during the 1st quarter. City Holding Co. now owns 7,767 shares of the company’s stock valued at $494,000 after purchasing an additional 31 shares during the last quarter. Camelot Portfolios LLC increased its position in shares of Merck & by 0.4% during the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after purchasing an additional 33 shares during the last quarter. Finally, Stillwater Investment Management LLC increased its position in shares of Merck & by 0.8% during the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock valued at $296,000 after purchasing an additional 38 shares during the last quarter. Institutional investors and hedge funds own 73.02% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE MRK) traded up 0.06% on Friday, reaching $66.16. The company’s stock had a trading volume of 14,685,767 shares. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The company has a market capitalization of $180.44 billion, a price-to-earnings ratio of 35.82 and a beta of 0.81. The company’s 50-day moving average is $63.41 and its 200 day moving average is $63.72.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.93 earnings per share. Equities analysts anticipate that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is 76.11%.

WARNING: “Merck & Company, Inc. (MRK) Holdings Boosted by Catawba Capital Management VA” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://ledgergazette.com/2017/09/16/merck-company-inc-mrk-holdings-boosted-by-catawba-capital-management-va.html.

MRK has been the subject of several research analyst reports. Jefferies Group LLC reaffirmed a “sell” rating and set a $52.00 target price on shares of Merck & in a research report on Sunday, August 20th. Credit Suisse Group decreased their target price on Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research report on Wednesday, August 30th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. BMO Capital Markets reaffirmed a “buy” rating and set a $72.00 target price on shares of Merck & in a research report on Friday, September 8th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $66.00 target price (up from $64.00) on shares of Merck & in a research report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $70.00.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply